<- Go Home
Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland.
Market Cap
CHF 5.1B
Volume
112.9K
Cash and Equivalents
CHF 29.1M
EBITDA
CHF 199.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 211.7M
Profit Margin
31.23%
52 Week High
CHF 84.05
52 Week Low
CHF 43.34
Dividend
1.25%
Price / Book Value
3.73
Price / Earnings
37.74
Price / Tangible Book Value
3.79
Enterprise Value
CHF 5.1B
Enterprise Value / EBITDA
25.61
Operating Income
CHF 164.6M
Return on Equity
10.07%
Return on Assets
5.66
Cash and Short Term Investments
CHF 29.1M
Debt
CHF 60.9M
Equity
CHF 1.4B
Revenue
CHF 677.9M
Unlevered FCF
-CHF 227.9M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium